Anixa Biosciences (ANIX) News Today

EF Hutton Acquisition Co. I raised Anixa Biosciences to a "strong-buy" rating in a research note on Wednesday.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 21,646 shares of the company's stock in a transaction that occurred on Tuesday, July 30th. The stock was acquired at an average price of $3.06 per share, with a total value of $66,236.76. Following the acquisition, the director now owns 890,754 shares in the company, valued at $2,725,707.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies bought 5,000 shares of the firm's stock in a transaction on Friday, July 26th. The stock was acquired at an average cost of $3.09 per share, with a total value of $15,450.00. Following the completion of the purchase, the director now owns 115,000 shares of the company's stock, valued at approximately $355,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Wednesday.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 10,738 shares of the company's stock in a transaction on Friday, June 7th. The shares were acquired at an average price of $2.52 per share, with a total value of $27,059.76. Following the transaction, the director now directly owns 848,775 shares of the company's stock, valued at $2,138,913. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

HC Wainwright dropped their price target on Anixa Biosciences from $12.00 to $7.00 and set a "buy" rating for the company in a report on Monday.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CFO Michael Catelani bought 6,250 shares of the firm's stock in a transaction that occurred on Friday, June 7th. The stock was purchased at an average price of $2.40 per share, with a total value of $15,000.00. Following the completion of the purchase, the chief financial officer now owns 35,211 shares in the company, valued at $84,506.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 554,300 shares, a decrease of 12.3% from the April 30th total of 632,100 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average daily volume of 111,000 shares, the short-interest ratio is presently 5.0 days.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 15,009 shares of the firm's stock in a transaction dated Tuesday, April 9th. The stock was purchased at an average cost of $3.28 per share, with a total value of $49,229.52. Following the transaction, the director now owns 838,037 shares in the company, valued at $2,748,761.36. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Anixa Biosciences in a report issued on Thursday, March 21st. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.1

HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Anixa Biosciences in a research report on Thursday.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 618,200 shares, a growth of 8.2% from the February 14th total of 571,500 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average trading volume of 211,200 shares, the days-to-cover ratio is currently 2.9 days.

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies purchased 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The stock was bought at an average price of $3.63 per share, with a total value of $36,300.00. Following the transaction, the director now directly owns 110,000 shares in the company, valued at $399,300. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.